Personalized Therapy Promising in Metastatic Breast Cancer

Share this content:
Personalized Therapy Promising in Metastatic Breast Cancer
Personalized Therapy Promising in Metastatic Breast Cancer

MONDAY, June 4, 2018 (HealthDay News) -- A highly personalized therapy targeting multiple tumor antigens shows promise for metastatic breast cancer, according to a research letter published online June 4 in Nature Medicine.

Nikolaos Zacharakis, Ph.D., from the National Institutes of Health in Bethesda, Md., and colleagues present the case of a 49-year-old woman with chemorefractory hormone receptor-positive metastatic breast cancer who was treated with tumor-infiltrating lymphocytes that were reactive against mutation versions of four proteins (SLC3A2, KIAA0368, CADPS2, and CTSB).

The researchers found that adoptive transfer of these mutant-protein-specific tumor-infiltrating lymphocytes with interleukin-2 and checkpoint blockade mediated a reduction in cancer, with the target tumor burden reduced by 51 percent at the first evaluable time points six weeks after cell transfer. At 22 months after cell transfer, all target and nontarget lesions had resolved radiologically.

"Metastatic breast cancer can be a heterogeneous disease, and this patient demonstrated that a personalized therapy tailored to target the unique somatic mutations presented by the autologous tumor of the affected individual can mediate complete durable cancer regression," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Incident Contrast Sensitivity Common in Middle-Aged Adults

Incident Contrast Sensitivity Common in Middle-Aged Adults

Factors linked to elevated risk include cadmium level in highest quintile, older age, more plaque sites

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Reduces all-cause mortality, cardiovascular-related hospitalizations compared with placebo

Scribes Improve Physician Workflow, Patient Interaction

Scribes Improve Physician Workflow, Patient Interaction

Scribes lower EHR documentation burden for doctors and increase time spent interacting with patients

is free, fast, and customized just for you!




Already a member?

Sign In Now »